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Abstract
Purpose Outpatient subcutaneous therapies are becoming
increasingly common. A literature search failed to find
produced any studies on application problems pertaining to
the self-injection of low-molecular-weight heparins
(LMWH) in a heterogeneous outpatient population under
daily-life conditions. We therefore designed a study with
the aim of recording drug use problems, patient satisfaction,
compliance, problems arising from the injection site
(abdomen vs. thigh), and residual drug volumes in pre-
filled syringes used in self-injection therapy.
Methods Patients were recruited in community pharmacies
by 95 trained Master's students in pharmacy. Data were
collected during recruitment and by means of structured
questionnaire-based telephone interviews that were carried
out at the beginning and the end of the LMWH treatment.
Results The median age of the 213 patients enrolled in the
study was 54 years [interquartile range (IQR) 39–70 years];
of these, 15.5% had their injections administered by a third
person. The rate of self-reported non-compliance was
17.1%. At least one relevant problem was recorded in
85.0% of the cases. At the end of the treatment, 38.9% of
the patients stated self-administration of the injections
required some effort. The preferred injection site was
the thigh (68.5%). An overall mean residual drug
volume ≥10.0% was detected for 3.9% of the patients. If
residual drug was present, a median of 11.2% (IQR 8.6–
17.6%) of the total drug volume had not been injected.
Patients injecting into the thigh showed a higher risk of
leaving residual medication (odds ratio 2.16, 95% confidence
interval 1.04–4.51).
Conclusions Most patients had drug use problems, whereas
no clear factors were associated with non-compliance, the
injection site (apart from residual drug), and discomfort or
effort required (apart from prior injection use).
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Introduction
Low-molecular-weight heparins (LMWH) are frequently
used for the prevention and treatment of venous thrombo-
embolism [1–3]. There is strong evidence demonstrating
the good benefit-to-risk ratio and cost-effectiveness of
venous thromboembolism prophylaxis [1]. Treatments with
LMWH are often started during a hospital stay or at
hospital discharge and followed up by daily subcutaneous
(s.c.) self-injections in an ambulatory setting for a period of
time varying from days to weeks. Results from published
studies demonstrate that home treatment of deep vein
thrombosis with LMWH is at least as safe and effective
as inpatient treatment—and may save costs and increase
patient satisfaction [4, 5].
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Approaches involving outpatient s.c. therapies for the
treatment of different diseases are becoming increasingly
common. In addition to being used for the injection of the
LMWH, pre-filled ready-to-use syringes are readily available
for the treatment of multiple sclerosis (e.g., interferons),
arthritis (e.g., methotrexate, tumor necrosis factor alpha
blocker), anemia (e.g., erythropoietin), cancer (e.g., interfer-
ons), female infertility (hormones), hepatitis B and C (e.g.,
interferons) as well as for contraception (medroxyprogester-
one acetate). Additional devices are pens, which are used by
diabetic patients (insulin, exenatide) or for migraine treatment
(e.g., sumatriptan), injectors, which are often used in the
treatment of osteoporosis (recombinant parathyroid hormone
analogue), or vials/ampules, where preparation is needed
before injection (e.g., female infertility, cancer, multiple
sclerosis and enfuvirtide in human immunodeficiency virus
treatment). A search of the literature failed to identify studies
focusing on drug use problems and/or the practical aspects of
s.c. self-administration beside the LMWH in an outpatient
setting. Rather, most of the studies on the self-injection of
other agents concentrated on other aspects of this therapeutic
approach, such as pharmacokinetics, effectiveness, safety,
and patient satisfaction.
Discussions on the preferred injection site are ongoing,
especially with LMWH [6–9]. Case reports of hematomas
in the abdominal wall and rectus sheath due to s.c.
injections into the abdominal wall are rare, but appear
regularly in the literature [10–18]. Risk factors seem to be
advanced age, female gender, polymorbidity, renal impair-
ment, cough, therapeutic LMWH dosages, and concomitant
use of anticoagulants. There is no expert consensus on the
preferable injection site, often not even within one hospital.
Patients who have already received LMWH treatment in the
past are especially irritated when they receive a complete
new set of instructions. Even more confusing is the wording
for the abdomen and thigh injection sites: for example,
eight different terms pertaining to the abdomen and five
descriptions of the injection in the thigh were found in
Swiss package inserts and leaflets. Expressions such as
“ventral, collateral region of the abdomen” or “outer upside
of the thigh” are difficult to visualize, especially by the
layperson. The injection sites “back of the upper arm” or
the “gluteal area” are rarely used, as these sites are
unsuitable for self-injections. In addition to the injection
site, a proper injection technique contributes to a safe and
positive outcome, i.e., injecting slowly into a skin fold to
reduce site pain and bruising [19, 20] as well as to ensuring
that the injection is subcutaneous and not intramuscular.
Little information on drug use problems and compliance
with LMWH treatment in outpatients is available in the
literature [21–24]. Previous studies only investigated
orthopedic patients recruited from selected clinics or
hospitals. All of these study participants received educa-
tional programs that included instruction in the injection
technique, performing their first self-injection in the
presence of a medical professional (nurse or physician),
and (occasionally) written information material or a video
tape. Study sizes ranged from 40 to 214 patients. However,
we were unable to find any study involving a heteroge-
neous patient population receiving standard care.
We therefore designed a prospective cross-sectional
study using pharmacy customers treated with LMWH as a
convenient representative population receiving s.c. thera-
pies with pre-filled syringes under daily life conditions. Our
aim was to record drug use problems, patient satisfaction,
and patient compliance. The results should highlight
potential areas for improvements in patient care through
specific interventions. The secondary aims were to identify
differences in problems arising due to the choice of
injection site (abdomen vs. thigh) and to determine residual
drug volumes in the used syringes.
Methods
Setting and study population
Patients were recruited sequentially in community pharma-
cies by pharmacy students during their internship. Between
January and May 2008, 95 Master’s students of the two
German-speaking universities of Basel and Zurich were
instructed to recruit and interview ambulatory LMWH
patients. In advance, the students received: (1) a detailed
oral study briefing and written information; (2) documents
for data collection; (3) instructions in the s.c. injection
technique, including clinical training by nursing staff.
A broad range of inclusion criteria was deliberately
chosen with the intention of reaching a varied sample of
LMWH patients reflecting all aspects of daily life: out-
patients aged ≥18 years, all brands of LMWH (pre-filled
syringes), prophylactic or therapeutic use, new or long-term
prescription, first or previous outpatient s.c. treatment, all
therapy durations, self-injection or application by another
person (e.g. family member, nursing service), and no
comprehension difficulties due to language.
Data collection
Routine prescription validation by each community pharmacy
(standard care) was performed when a LMWHwas requested.
The study was explained to the person bringing the
prescription (the patients themselves or another person) and
instructions were given on the s.c. injection technique if
required. If the patient met the inclusion criteria and oral
consent was obtained, written patient information and a sharps
collector (E-safe) for the used syringes were delivered.
110 Eur J Clin Pharmacol (2011) 67:109–120
Telephone interview
At a pre-arranged date—either 1–3 days after the prescrip-
tion was filled or at start of the LMWH treatment—an
extensive structured questionnaire-based telephone inter-
view was carried out. The trained students filled in the
questionnaire by interviewing only the patient, even if the
injections were carried out by another person. The survey
consisted of open questions wherever possible, and
patients’ spontaneous answers were recorded. Multiple
answers were accepted, but no answer suggestions were
allowed. The reason for carrying out this telephone
interview at an early point in the LMWH treatment was to
evaluate drug use problems, the amount of effort required
to self-inject, and discomfort at the beginning of the
treatment. Self-estimations were assessed on two different
scales: (1) an 11-point scale to rate discomfort (0=very
uncomfortable; 10=very comfortable) and (2) a 4-point
scale to assess the degree of effort required (1=no effort
required at all; 2=nearly no effort required; 3=sometimes
effort required; 4=considerable effort required) and drug
use problems in general. In addition, the interview gathered
information on patient and medication characteristics, self-
management, knowledge, quality of care, and patient
satisfaction. If patients confirmed being impaired in their
daily activities due to any kind of problem, pain, injury, or
illness associated with the arm, shoulder, or hand, we rated
the patient as being impaired in fine motor skills.
Final interview
After completion of the s.c. therapy, a short, structured
questionnaire-based interview was carried out with each
patient when he/she returned the sharps collector to their
community pharmacy for professional disposal. The ques-
tions focused on the amount of effort required to maintain
the treatment (none at any time; only in the beginning of
treatment; occasionally; during the whole treatment period),
on discomfort at the end of treatment, and on self-reported
non-compliance. Exactly when this short interview took
place depended on each individual’s treatment duration.
Patients were instructed to return their sharps collector after
6 weeks if the treatment period was longer.
The data collection was anonymized by assigning a code
to each patient. Participants were asked to give oral consent
each time they were contacted. The study protocol was
approved by the local Ethics Committee of Basel (EKBB
95/07).
Analysis of used syringes
The returned sharps collectors were examined for the
following: identification of patient code and syringe type;
number of used syringes; number of syringes with
recapping (illegitimate replacement of the needle shield—
sometimes called needle cap—after injection); number of
syringes with a visible residual drug volume; amount of
residual drug volume; number of syringes with a correctly
installed safety device for the prevention of needle stick
injuries after injection.
Because the residual drug had often evaporated (espe-
cially in syringes without recapping), its volume could only
be reliably determined by measuring the distance between
the plunger and the end of the syringe barrel. Accordingly,
the residual volume could be estimated by comparison with
an unused syringe of the same type (taking the air bubble
into consideration). To obtain this reference distance, we
calculated the mean values of at least three syringes of each
type. The mean residual drug volume (as a percentage) was
defined as being equal to the calculated mean residual
distance (percentage). Unused syringes were not included
in this analysis. We considered a residual drug volume to be
relevant if ≥10.0% of the total volume remained in the
syringe.
Statistical analysis
The interview data sheets were processed with the
automated form-processing software TELEform ver. 10.2
(Cardiff Software, Vista CA). To avoid potential errors, we
verified the data transfer by visually comparing the written
sheet and on-screen data. All data were then checked for
plausibility by the first author. Free-text answers and
comments were recorded separately and grouped during
the plausibility-process by the first author. Missing data
were complemented in the database according to the
annotations if possible. Statistical analysis was performed
using SPSS for Windows ver. 17.0 (SPSS, Chicago, IL).
In the descriptive analysis, medians and interquartile
ranges (IQR; 25th to 75th percentile) were calculated.
Pearson’s chi-square test was used to investigate possible
associations between two variables in a four-fold table. For
unrelated group analyses, the non-parametric tests Mann–
Whitney and Kruskall–Wallis were chosen. Analog tests for
normal distribution [Student’s t test, analysis of variance
(ANOVA)] were employed if the results differed. Statistical
significance was set at p≤ 0.05.
Results
Of the 402 people approached by the pharmacy students
when they went to a community pharmacy with a
prescription for LMWH, 223 agreed to participate in the
study and 144 completed the study (Fig. 1). Drop-outs did
not differ from study completers in terms of age (p=0.37,
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Mann–Whitney test), sex (p =0.93, chi-square test), previous
outpatient s.c. injection therapies (p=0.76, chi-square test),
injections administered by another person (p=0.06, chi-square
test), little instruction (no oral instruction in the injection
technique or only by the pharmacy; p=0.66, chi-square test),
the degree of effort required (p=0.56, Mann–Whitney test),
discomfort (p=0.91, Mann–Whitney test), or fine motor skills
(p=0.40, chi-square test). Patient and medication character-
istics are listed in Table 1.
Table 2 summarizes patients’ self-reports on application
problems, self-management, knowledge, non-compliance,
and quality of care experienced (including patient satisfac-
tion). We defined drug use problems to be relevant when:
(1) patients were insufficiently informed about the injection
site or technique; (2) injections were administered by
another person; (3) recapping was carried out; (4) difficul-
ties with removal of the needle shield existed; (5) there
were discrepancies with prescribed therapy duration, daily
injections, and injection time. At least one of these
problems was reported in 181 (85.0%) patients. The
community pharmacy instructed 10.8% of the patients in
the injection technique.
Self-reported non-compliance showed no association
with age (p=0.85, Mann–Whitney test), previous outpatient
s.c. injection therapies (p=0.94, chi-square test), injections
administered by another person (p =0.18, chi-square test),
the degree of effort required (p=0.53, Mann–Whitney test),
little instruction (p =0.23, chi-square test), discomfort (p=
0.15, Mann–Whitney test), or fine motor skills (p=0.24,
chi-square test). No significant associations were seen
between the estimations of effort required and discomfort
experienced with the variables first self-injection under the
supervision of a medical professional (p=0.62 and 0.56,
respectively; Mann–Whitney test), little instruction (p=0.66
and 0.22, respectively; Mann–Whitney test), injections
administered by another person (p=0.32 and 0.83, respec-
tively; Mann-Whitney test), or the injection sites abdomen
versus thigh (p=0.60 and 0.91, respectively; Mann–Whitney
test). Patients with experience gained from previous outpatient
s.c. injection therapies had less discomfort and the injections
required less effort (p=0.011 and 0.022, respectively; Mann–
Whitney test). Comfort/confidence with the injections and the
degree effort required showed a Spearmen’s correlation
coefficient of r= −0.5 (p<0.001).
Of the 144 patients completing in the study, 126
estimated their comfort and effort required at the beginning
and at the end of treatment (18 patients did not assess these
parameters at the final interview as the injections were
administered by another person). At the beginning of the
therapy, 75.4% estimated their confidence with self-
injecting as high (scale levels 8–10), while 32.5% reported
that the injection required some effort. At the end of
treatment, the corresponding values were 81.7% and
38.9%, respectively. Comfort and effort required did not
change significantly over time (p=0.08 and 0.13, respec-
tively, McNemar test). Nine (7.1%) persons stated that the
injections required effort throughout treatment, resulting in
complete non-compliance in one case. Ten of the 126
patients sometimes had their injections administered by
another person.
A comparison of the abdomen and thigh injections sites
revealed no significant associations between puncture (p=
0.14, Mann–Whitney test) or injection (p=0.38, Mann–
Whitney test) being unpleasant or painful and the side
Fig. 1 Study flowchart with
numbers of patients and
reasons for dropout. LMWH
Low-molecular-weight
heparins
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effects hematoma (p=0.50, chi-square test), mild injection
site irritation (p=0.34, chi-square test), and site pain (p =
0.24, chi-square test).
When only patients who always or sometimes self-
administered the LMWH were considered (n=187), signif-
icant differences between the level of difficulty encountered
in removing the needle shield were found between the
different brands of syringes needle shield (p=0.037,
Kruskal–Wallis test). Based on pairwise differences, the
needle shield of Fragmin was rated as significantly easier to
Table 1 Characteristics of study sample (ntotal=213)
Patient and clinical characteristics n (%)a Missing data n (%)
Patient characteristics
Age (years) 54 (39–70) 2 (0.9)
Males 108 (50.7) 2 (0.9)
Education: 14 (6.6)
mandatory school 24 (11.3)
skilled worker 123 (57.7)
technical college + university 52 (24.4)
Previous outpatient s.c. injection therapies 89 (41.8) 1 (0.5)
Impairment in daily living due to arm, shoulder, or hand 29 (13.6) 9 (4.2)
Arthritis in arm, shoulder, or hand 32 (15.0) 20 (9.4)
Impaired vision (using glasses or contact lenses) 27 (12.7) 26 (12.2)
Medication characteristics
Medication 0 (0.0)
Fragmin (dalteparin) 99 (46.5)
Fraxiparine (nadroparin) 63 (29.6)
Clexane (enoxaparin) 33 (15.5)
Fraxiforte (nadroparin) 9 (4.2)
Sandoparin (certoparin) 9 (4.2)
Application once daily 171 (80.3) 1 (0.5)
Not specified on prescription 27 (12.7)
Concomitant medication with an increased bleeding risk (not necessarily on the same prescription)
Anticoagulant (acetylsalicylic acid, phenprocoumon, acenocoumarol, clopidogrel) 68 (31.9) 4 (1.9)
anticoagulant stopped during LMWH treatment 28/68 (41.2) 3/68 (4.4)
Prescribed analgesic 146 (68.5) 7 (3.3)
only paracetamol 37/146 (25.3) 0/146 (0.0)
Self-medication with analgesics: 20 (9.4) 2 (0.9)
only paracetamol 9/20 (45.0) 0/20 (0.0)
Reason for LMWH treatment (multiple answers possible) 0 (0.0)
Surgery/injury of
lower limb 112 (52.6)
hip 11 (5.2)
upper limb 7 (3.3)
Thrombosis, embolism 35 (16.4)
Perioperative management/bridging 16 (7.5)
Atrial fibrillation, myocardial infarction 8 (3.8)
Cancer 7 (3.3)
Pregnancy, hormone therapy 6 (2.8)
Abdominal surgery 6 (2.8)
Long-distance travel 4 (1.9)
Other 12 (5.6)
s.c., Subcutaneous, LMWH, low-molecular-weight heparins
a All data is presented as the number (n) with the percentage in parenthesis with the exception of ‘Age’, which is presented as the median with the
interquartile range in parenthesis
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Table 2 Self-reported quality of care (including patient satisfaction), self-management, drug use problems, knowledge, and non-compliance
(ntotal=213)
Parameters on patients’ self-reports n (%)a Missing data n (%)
Quality of care and patient satisfaction
Oral instruction in injection technique (previous and present treatment): 0 (0.0)
None 10 (4.7)
Only by the pharmacy 8 (3.8)
Insufficiently informed about injection site 8 (3.8) 7 (3.3)
Insufficiently informed about injection technique 14 (6.6) 9 (4.2)
Alcohol swab provided 200 (93.9) 1 (0.5)
First self-injection in the presence of a medical professional:
Provided 111 (52.1) 0 (0.0)
helpful 97/111 (87.4) 12/111 (10.8)
Not provided, but desired 15/102 (14.7) 17/102 (16.7)
Delivery of leaflet:
Provided 41 (19.2) 8 (3.8)
helpful 33/41 (80.5) 3/41 (7.3)
Not provided, but desired 28/164 (17.1) 22/164 (13.4)
First injection administered by the pharmacist:
Provided 0 (0.0) 13 (6.1)
Not provided, but desired 9/200 (4.5) 42/200 (21.0)
All injections administered by the pharmacist:
Provided 0 (0.0) 12 (5.6)
Not provided, but desired 8/201 (4.0) 33/201 (16.4)
Delivery of sharps collector:
Provided 203 (95.3) 0 (0.0)
helpful 135/203 (66.5) 38/203 (18.7)
Not provided, but desired 0/10 (0.0) 4/10 (40.0)
Injection training into a “phantom” (injection pillow):
Provided 7 (3.3) 8 (3.8)
helpful 6/7 (85.7) 1/7 (14.3)
Not provided, but desired 10/198 (5.1) 33/198 (16.7)
Video tape:
Provided 1 (0.5) 10 (4.7)
helpful 0/1 (0.0) 0/1 (0.0)
Not provided, but desired 13/202 (6.4) 33/202 (16.3)
Self-management (multiple answers possible)
Injection site 0 (0.0)
Thigh 146 (68.5)
Abdomen 80 (37.6)
Back of the upper arm 2 (0.9)
Other 2 (0.9)
Injections administered by another person (sometimes or always) 33 (15.5) 0 (0.0)
by family member/friend 25/33 (75.8)
by medical professional 9/33 (27.3)
Reasons for not self-injecting: 5/33 (15.2)
needle phobia 9/33 (27.3)
fear of puncturing skin 8/33 (24.2)
severely disabled 4/33 (12.1)
family member is a medical professional 3/33 (9.1)
other 8/33 (24.2)
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Table 2 (continued)
Parameters on patients’ self-reports n (%)a Missing data n (%)
Illegitimate recapping 157 (73.7) 5 (2.3)
Application problems
Difficulties with removal of needle shield 28 (13.1) 1 (0.5)
Puncture is unpleasant/painful 105 (49.3) 3 (1.4)
Injection is unpleasant/painful 113 (53.1) 6 (2.8)
Degree of effort required to inject (scale: 1–4) 2 (1–3) 5 (2.3)
Confidence/lack of discomfort (scale: 0–10) 9 (7–10) 26 (12.2)
Side effects (multiple answers possible): 105 (49.3) 2 (0.9)
Hematoma at injection site 79 (37.1)
Mild injection site irritation/burning 36 (16.9)
Hematoma in general 16 (7.5)
Site pain 15 (7.0)
Exanthema 4 (1.9)
Bleeding tendency 4 (1.9)
Induration 4 (1.9)
Epistaxis 2 (0.9)
Other 9 (4.2)
no action taken by study participants 77/105 (73.3) 13/105 (12.4)
met criteria for reporting an adverse event to regulatory authority 1 (0.5) (arm exanthema) 0 (0.0)
Knowledge
Discrepancy with prescribed therapy duration 9 (4.2) 4 (1.9)
Not specified on prescription 59 (27.7)
Discrepancy with prescribed daily injections 3 (1.4) 3 (1.4)
Not specified on prescription 27 (12.7)
Discrepancy with prescribed injection time 7 (3.3) 3 (1.4)
Not specified on prescription 157 (73.7)
Nescience of reason for LMWH treatment 6 (2.8) 0 (0.0)
Nescience of potential interactions with NSAR 158 (74.2) 2 (0.9)
Nescience of potential side effects 116 (54.5) 2 (0.9)
Self-reported non-compliance (assessed at final interview with n=144 patients)
Difficulties with injecting the LMWH timely 15 (10.4) 2 (1.4)
Applications exceeding ± 2 h of assigned injection time 5 (3.5) 1 (0.7)
Skipping injections (n=146; completion of database according to annotations): 25 (17.1) 0 (0.0)
1 time 8/25 (32.0) 4/25 (16.0)
>3 times 5/25 (20.0)
Reason for skipping injections (multiple answers possible): 1/25 (4.0)
forgotten 11/25 (44.0)
early discontinuation 6/25 (24.0)
not being at home 2/25 (8.0)
otherb 7/25 (28.0)
NSAR, Non-steroidal anti-rheumatics
a All data is presented as the number (n) with the percentage in parenthesis with the exceptions of ‘Degree of effort required to inject’ and ‘Confidence/lack
of discomfort’, which are presented as the median with the interquartile range in parenthesis
b Injections every 2–3 days depending on appearance of leg pain; vomiting or abdominal pain; delayed filling of the prescription; skeptical towards LMWH;
news coverage about contaminated heparins; injection required too much effort (complete non-compliance); dropping a syringe leading to an insufficient
number of syringes
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remove than those of Clexane and Fraxiparine (p=0.021
and 0.003, respectively, Mann–Whitney test).
Post-injection needle guards were only found with
Fraxiparine and Fraxiforte devices. The needle guards
of all syringes in the sharps collectors were correctly
positioned by 22 (32.8%) of the 67 patients injecting
Fraxiparine or Fraxiforte (missing data: n=5); 24 (35.8%)
patients activated the safety device only partly, and 21
(31.3%) patients did not use the needle guards at all or not
properly (the protective guard is only securely locked in
place once a clicking sound is heard after sliding it over
the needle).
The sharps collectors of 180 patients contained a total of
3,218 syringes (median 10.5, IQR 8–26; range 1–100)
(Fig. 2). The pre-filled syringes had volumes of 0.2–1.0 ml
and distances between the plunger and the end of the
syringe barrel of 17.0–38.4 mm (including the air bubble).
An overall mean residual drug volume ≥10.0% was
detected for seven (3.9%) patients (median injection
volume 0.6 ml). The highest overall mean residual drug
volume was 17.9%, and was recorded for a patient who had
injected 13 syringes of 0.8 ml.
When only those syringes with residual amounts of
LMWH were considered, a median of 11.2% (IQR 8.6–
17.6%) of the liquid remained in the syringe. In other
words, if their syringes were not empty, 58 (59.8%) of the
97 persons affected had ≥10.0% of the total volume not
injected (Fig. 3). Comparisons between these 58 patients
and the remaining 122 participants showed no differences
in age (p=0.61, Mann–Whitney test), sex (p=0.72, chi-
square test), fine motor skills (p=0.53, chi-square test),
previous outpatient s.c. injection therapies (p=0.74, chi-
square test), injections administered by another person (p=
0.48; chi-square test), injection volumes (p=0.53, Mann-
Whitney test), the different brands (p=0.09, chi-square test),
or number of used syringes as an indication of therapy
duration (p=0.14, Mann–Whitney test). However, these 58
patients injected significantly less into the abdomen (p=
0.021, chi-square test) and significantly more into the thigh
[p=0.019, chi-square test; odds ratio 2.16, (95% confidence
interval (CI) 1.04–4.51)].
Optional free-text comments provided deeper insights
into the nature of the drug use problems. Handling
difficulties were reported by 33 patients (15.5%); the most
important of these are listed in Table 3.
A student observed that the majority of his pharmacy
customers’ complaints were at the beginning of treatment.
Fig. 2 Prevalence of syringes
with residual drug irrespective
of the volume amount
Fig. 3 Mean proportion of residual drug in used syringes still containing
medication. Only those syringes with residual amounts of LMWH (97
patients, 304 syringes; range 1–16 syringes) were considered in the analysis
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In contrast, one patient’s concerns increased towards the
end of a 4-week treatment. Another person would have
even changed from self-management to injections by
another person if the therapy duration was longer than the
actual 6 weeks. One patient injecting into the thigh had
more side effects when injecting 0.6 than 0.4 ml.
Two patients showed restraint in injecting into the thigh;
one chose the abdomen instead, and the second asked
another person to administer the injection. One person
noticed that hematoma generally developed more often
when injecting into the abdomen.
The support offered was not always satisfying and
highlights possible areas for improvement in patient care
(Table 4).
Discussion
With respect to outpatient s.c. therapies, drug use problems
appear to be very prevalent, diverse, and complex. They
may be associated with the injection itself or with the
handling of the injection-device. Notably, among the
participants in our study, 85.0% experienced at least one
relevant problem, with recapping being the most frequent
difficulty encountered: 73.7% of the patients replaced the
needle shields after injection, which is against recommen-
ded practice. At the end of the therapy, almost 40%
reported that the injection required some effort, and
17.1% admitted non-compliance. Medical professionals
are unable to ascertain potential patient problems in using
medication at first glance. As a result, any outpatient s.c.
therapy poses a challenge not only for the patients
themselves and their family/friends, but also for health
professionals. Therefore, adequate patient care and educa-
tion are crucial and should be optimized.
In our study, 15.5% of patients had their injections
performed by another person (75.8% of these by family
members or friends); of these, 51.5% of patients reported
that this was due to needle phobia or a fear of puncturing
the skin. A review of the literature shows a 13–37% non-
self-injecting rate [21–24], and in 46.9–66.0% of these
cases family members administered the injections [21, 24];
75.0% of those who refuse to self-inject report that it is due
to fear [21]. This fact should be considered when designing
patient education programs. If injections are given by a
family member, this person should be properly instructed.
Table 3 Handling difficulties (multiple statements per person possible)
Component/action Handling difficulty
Flap of paper backing on blister pack Too small to remove the syringe from its packaging
Removal of needle shield Tricky; difficulties due to single-handed removal; bending the needle; total liquid loss due to pulling the
plunger rod
Needle Too sharp; not sharp; twice blocked; bent
Air bubble Uncertainty whether air bubble needs to be removed; annoying; no air bubble
Injection Injection more painful with small injection angle (n=2); injection needs lots of force (n=2); uncertainty
concerning the insertion length of the needle into the skin; coordination difficult regarding quick insertion
of the needle vs. slow injection; high resistance when pushing the plunger rod in the beginning leading to
a sudden and quick injection; needle accidentally came out of the skin during injection; liquid loss during
first injection; early discontinuation due to lots of pain and problems during injection; injection by
another person, because of inability to self-inject into the back of the upper arm; setting back injection
time every day 15 min from 7 p.m. (injection time in hospital) to 11 p.m. (preferred injection time at home)
Recapping Needle stick injury; needle easily penetrates the soft needle shield
Syringe Syringe in general very small and hence difficult to handle (n=3); uncertainty whether total volume was
injected (n=3); dropping the syringe before injection (n =2); finger flange too small (n=2); difficulties
with positioning the needle guard of Fraxiparine
Table 4 Room for improvement in quality of care (multiple statements per person possible)
General improvements Specific improvements
More information On thromboembolism (n=4) and its prevention (n =2); on LMWH and side effects (n = 2)
Improved instruction in the
injection technique
Better instruction (n=9); increased patient involvement (n =8); instructions not only orally but with
demonstration of the injection technique (n =2); self-injections during the whole hospital stay and not only
on the day before hospital discharge (n =2); repetition of the instructions when collecting their prescription
Consistent instructions On injection angle (n=3); injection site (n =2); skin fold; air bubble
Better leaflets On terminology; font size; foreign languages
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Consequently, physicians, hospitals, and community phar-
macies should always be equipped with the latest leaflets.
There were no associations between patient character-
istics and outcome measures with effort required or
discomfort, with the exception of previous experience in
self-injecting. A possible explanation for the absence of
associations could be the heterogeneity of the study sample.
Discomfort and effort required did not change notably over
time. The level of comfort with the procedure was quite
high in general, with one reason probably being the fact
that 41.8% of the patients already had experience of
outpatient s.c. injection therapies (this patient group was
significantly more confident and felt less effort was
needed).
Important differences concerning difficulties with the
removal of the needle shield between different LMWH
brands were observed, which confirms the results of a
previous investigation [25]. Only one third of patients
injecting Fraxiparine or Fraxiforte applied the needle
guards of all their used syringes accurately, and one third
did not use them at all or used them improperly. Ironically,
the danger for needle stick injuries increases when the
needle guard is positioned but not locked in position, as
protection is assumed but not provided. There is certainly
room for improvement in this area through better patient
information and education, particularly as correctly fitting
the guard requires considerable force and coordination and
the mechanism is poorly marked. Clexane and Arixtra have
pre-filled syringes equipped with new automatic safety
devices; the protective shield is triggered when the syringe
is empty. In addition to preventing needle stick injuries, the
Clexane and Arixtra syringes ensure that the whole amount
is injected. In our study, there were no patients prescribed
with Arixtra, and the new Clexane device and the new
Fragmin Needle-Trap were not yet on the market in
Switzerland.
Whether additional drug use problems were also men-
tioned by the participant when he/she was answering the
questions posed during the telephone interview depended
on the participant’s openness for further conversation. It can
be assumed that these anecdotic application problems
would have been noted more frequently if they were asked
for systematically. An example is the single statement of
one participant about having more side effects when
injecting 0.6 than 0.4 ml into the thigh, which confirms
the results from another study [26]. Thus, it is likely that
not all problems were revealed, and those that were may be
more multifaceted than previously imagined.
Prescriptions were often incomplete with regards to
therapy duration (27.7%), number of daily injections
(12.7%), and injection time (73.7%). Missing written
information makes patient care demanding. The probably
unintentional single under- or overdoses due to a shift in the
time interval of 10–12 h in comparison to the prescribed
injection time occurred at a sensitive and susceptible
moment after hospital discharge or at the beginning of
treatment in the ambulatory setting. It can be expected that
this was a much more common occurrence than the five
observed cases, as the injection time was not given by
73.7% of patients. As such time-shifts generally happen
unknowingly, patients would not have mentioned it when
assessing their own compliance.
Concomitant self-medication with non-steroidal analge-
sics did not seem to play an important role, although only
25.8% of the participants knew about potential drug
interactions with LMWH. The participants also showed a
lack of knowledge of potential side effects. Overall, the
assistance provided was appreciated by patients, but the
amount of help needs to be increased.
Two thirds of the patients injected into the thigh and one
third into the abdomen. Associations with local side effects
or the puncture hole and injection being painful were not
significant. In additional free-text answers, however, a
number of patients mentioned problems comparing the
two injection sites. The literature also seems to be
ambiguous on this point: a Brazilian study reported that
hematomas were observed in 83.7% of patients and that the
incidence of hematomas was higher if the LMWH
injections were administered into the thigh [27]. In contrast,
in a special series of patients following standard hernioto-
mia, hematoma appeared in 25% of the cases when the
patients injected into the abdomen and in 9% when they
injected into the thigh [9]. Other investigations comparing
local side effects of LMWH according to the two injection
sites were not found. In a study with s.c. injections of
enfuvirtide, injection site reactions were common but mild,
and their incidence was higher with injections into the
abdomen than into the thigh or arm [28]. Patients using a
sumatriptan self-injector experienced more bleeding and
local pain when injecting into the thigh compared to the
gluteal area; only 15% preferred the thigh as injection site
[29].
Every sixth person (17.1%) admitted to having skipped
injections. In similar studies, non-compliance rates of 4.5–
28.3% with different definitions of non-compliance were
found [21–24]. The main reason in the study of Spahn was
forgetfulness (94.1%), while 13.1% of the patients discon-
tinued early; all patients younger than 20 years were
classified as unreliable and compliance was dependent on
whether injections were self-administered [21]. Our study
showed a wider variety of reasons for non-compliance, with
the most important being forgetfulness (44.0%) and early
discontinuation (24.0%). We were unable to identify possible
risk factors for self-reported non-compliance, possibly
because only 25 patients actually admitted having skipped
injections, or the diverse reasons for non-compliance.
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Our original objective of determining patients’ taking
compliance by comparing the number of used syringes with
the prescribed therapy duration turned out to be impossible.
In 36.2% of the final interviews, the date of the last
injection was not provided, and in 27.7% and 12.7% of the
prescriptions, respectively, therapy duration and application
frequency were not specified. In addition, terms such as
“treatment until complete mobilization/international nor-
malized ratio twice in therapeutic range/next visit with
physician” did not enable the date of the last injection to be
estimated reliably. Furthermore, the prescription date did
not necessarily correlate with the day of discharge or start
of LMWH treatment. Similarly, a patient could be fully
compliant despite a delay in filling the prescription as—
particularly on weekends or public holidays—syringes are
often dispensed by hospitals or physicians to ensure
therapeutic coverage. For various reasons, all used syringes
were not discarded into the sharps collector: delayed
delivery of sharps collector, injection with physician during
consultation, not being at home, flights, holidays, and
delivery of syringes by the hospital or physician.
The determination of the residual drug volumes enabled
us to partially objectify patients’ compliance: residual drug
volumes were found rather sporadically, and almost half of
the patients had no residual drug in any syringe. The overall
mean residual drug volume was low and negligible, but the
total injection volume seemed to have an influence,
possibly as a result of rising tissue resistance due to the
injection of higher volumes. This has a particular impact
when LMWH are used for the treatment of thromboemb-
olisms as higher volumes are administered and patients are
at greater risk. If residual drug was present, however, it
tended to be of pharmacological relevance. It can be
expected that some of these injections were stopped early
on purpose.
Patients injecting into the thigh showed a higher risk of
leaving residual volumes, which may be due to the smaller
area of s.c. tissue in the thigh compared to the abdomen.
We therefore recommend that patients injecting high
volumes or injecting into the thigh be advised to monitor
closely whether the syringe is empty and to be aware that
they might need more force towards the end of the
injection. Other risk factors for residual volumes could
not be identified. Sufficient evidence was not collected on
this aspect, probably because the therapy durations were
mostly short, with a median of 10.5 syringes in the sharps
collectors. It has also to be taken into account that almost
half of the patients (47.2%) had to inject only small
volumes of ≤0.3 ml, and a minority of 9.4% injected
volumes of ≥0.7 ml.
The strength of our study is the heterogeneous study
population, covering a broad spectrum of drug use prob-
lems and reflecting daily life activities. Not only compar-
atively healthy patients participated in our study (e.g., those
with a foot injury, long-distance travelers), but also
seriously ill persons, such as patients with pulmonary
embolism, lung transplantations, or paraplegia. However,
categorization of such a study population is difficult. The
community pharmacies were distributed more or less
throughout Switzerland, which ensured that possible re-
gional differences in the quality of care on the part of the
physicians, hospitals, and community pharmacies were
taken into account.
The main limitations of our study are the data collection
by 95 students, a consent rate of only 55.5%, and a possible
bias due to patient selection. Polymorbid or cumbersome
pharmacy customers were less likely asked to take part in
the study, whereas regular or pleasant customers were more
often invited to participate. Furthermore, interested and
motivated patients are more likely to participate in a study
and to be more compliant, reflecting daily life in a much
too positive way. Another weakness is the dropout rate of
32.4% at the final interview, setting constraints on the
conclusions that could be drawn on self-reported non-
compliance and the estimations of comfort or effort
required in the course of the therapy duration. As no
prescription duplicate was requested and data collection
was anonymous, no retracing or access to medical history
was possible. Therefore, the results are based on patients’
self-reports only. Our determination of the residual drug
volume by measuring the distance between plunger and the
end of the cylindrical body was the most reliable
measurement, but the approach has limitations: as the
liquid had often evaporated, we were unable to recognize
whether we were measuring only missing liquid or the
missing liquid together with the air bubble. Thus, the
results are only estimations, although they are helpful in
providing an impression of the magnitude of the problem.
Hence, the true mean residual drug volumes may even be
smaller.
Conclusion
Low-molecular-weight heparins represent a good model for
studying outpatient s.c. therapies in primary care. Among
our patient cohort, 85.0% reported some relevant drug use
problem, whereas no clear factors were associated with
non-compliance, the injection site (beside residual drug),
and discomfort or effort required (beside prior injection
use). Around 4% of patients had a considerable mean
residual drug volume (≥10.0%) in their syringes, with a
higher risk of leaving medication when injection was into
the thigh. The challenge facing not only for pharmacists but
all health professionals as well as the pharmaceutical
industry (design of injection-device and instruction leaflets)
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is to successfully contribute to a successful therapy. From a
patient’s point of view, injections require some effort.
Therefore, it can be imagined that injection-free therapies
for patients on chronic antithrombotic therapy would be
appreciated.
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